My watch list
my.bionity.com  
Login  

Endocrinology Market to 2018 - Advanced Injection Devices for Growth Hormone and Somatostatin will Improve Ease of Use for Patients

GBI Research, the leading business intelligence provider, has released its latest research “Endocrinology Market to 2018-Advanced Injection Devices for Growth Hormone and Somatostatin will Improve Ease of Use for Patients”, which provides insights into the endocrine disease therapeutics market until 2018. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts. The report provides an in-depth analysis of the major endocrine markets including growth hormone deficiency market, acromegaly market, male Hypogonadism market and hypothyroidism market. The report also provides the share of generics in the global endocrinology as well as in each indication market. The report examines the global endocrine disorders treatment usage patterns. It provides the geographical distribution of growth hormone deficiency, acromegaly, male hypogonadism, hypothyroidism and markets across the US, the top five countries of Europe and Japan. The report also includes insights into the endocrinology Research and Development (R&D) product pipeline and explores the competitive landscape, including major players in the market. Finally, the report includes analysis on Mergers and Acquisitions (M&A) and licensing agreements that took place in the endocrinology market.

GBI Research’s analysis shows that the overall global endocrinology market for the four indications was valued at $6.0 billion in 2010. It grew from $4.0 billion in 2004 at a CAGR of 6.9%. The market is expected to witness series of patent expiries , generic erosion and possible launches of novel molecules. The market is expected to witness comparatively moderate growth with a CAGR of 8.0% between 2010 and 2018, and is estimated to reach $11.2 billion in 2018. Patent expiries of blockbuster drugs such as Sandostatin LAR, Norditropin will restrict the growth of the market. The rapid uptake of novel dosage forms and formulations of existing drugs will increase the number of patients on treatment. Increased awareness among the general population about rare endocrine disorders will lead to an increase in market size in the forecast period.

Report Highlights
GBI Research, the leading business intelligence provider, has released its latest research “Endocrinology Market to 2018 - Advanced Injection Devices for Growth Hormone and Somatostatin will Improve Ease of Use for Patients”, which provides insights into endocrinology until 2018. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts. The report provides an in-depth analysis of the major diseases including growth hormone deficiency, acromegaly, male hypogonadism and hypothyroidism. The report also provides the share of generics in the global endocrinology market as well as in each indication market. The report examines the global treatment usage patterns for each major disease. It provides the geographical distribution of growth hormone deficiency, acromegaly, male hypogonadism and hypothyroidism market across the US, the top five countries of Europe and in Japan. The report also includes insights into the endocrine therapeutics Research and Development (R&D) product pipeline and explores the competitive landscape including major players in the endocrinology market. Finally, the report includes analysis on Mergers and Acquisitions (M&A) and licensing agreements that took place in the endocrinology market.

GBI Research analysis shows that the endocrinology market is one of the competitive therapeutic segments with strong growth potential. Expensive biological therapies used in the treatment of endocrine disorders, the launch of novel drugs and increased usage of easy to use improved formulations of biologics are set to drive the endocrinology market.

Global Endocrinology Market is Set to Show Moderate Growth in Near Future

GBI Research valued the global endocrinology market at $6 billion in 2010, a CAGR of 6.9% from 2004 to 2010. The market is estimated to reach $11.2 billion in 2018, indicating a CAGR of 8.0% during the period 2010-2018. The acceptability of newer formulations of existing drugs, increased use of easy to use prefilled injection devices and expected launches of novel drug molecules in major therapy areas will contribute to the growth in the endocrinology market in the forecast period.

Acromegaly and growth hormone deficiency are the two major revenue generating therapy areas in the endocrinology market. The patent expiries of recombinant human growth hormone drugs such as Pfizer’s Genotropin, Eli Lilly’s Humatrope and F. Hoffmann La Roche’s Nutropin have already paved way for the entry of biogenerics in the growth hormone deficiency market. Furthermore patent expires of Novartis’s acromegaly drug Sandostatin LAR (2014 in the US) and Novo Nordisk’s Norditropin (2015) in the forecast period will accentuate the biogeneric erosion in forecast period in the endocrinology market.

The expected growth in the endocrinology market in the forecast period will be contributed by the expected launches of few promising molecules such as PLB03002, Arimidex, Pasireotide and C2L. Arimidex is a novel drug whereas PLB03002 is an improved formulation of recombinant human growth hormone for the treatment of growth hormone deficiency. Pasireotide, is a novel somatostatin analogue with high receptor affinity, and C2L is an improved formulation of octreotide being developed for the treatment of acromegaly.

Top Four Companies Contribute over 50% of the Global Endocrinology Therapy Area Sales

In 2010, the global endocrinology market was valued at $6.0 billion, with over 50% of the revenue attributable to the endocrinology specific sales of the leading four pharmaceutical companies in the sector: Pfizer, Abbott, Novartis and Novo Nordisk. Pfizer dominated the endocrinology market, with its drugs Genotropin, Somavert and Levoxyl. Somavert and Levoxyl became part of Pfizer through the recent acquisitions of Pharmacia and King Pharmaceuticals, respectively. The share of Pfizer is expected to decrease in the near future as biosimilars of Genotropin which entered the market have been leading to decline in branded Genotropin sales. Abbott is the second largest player in the endocrinology market with 13% of market share contribute by its drugs Synthroid and Androgel 1%. Novartis constitutes 11% of the market share with its acromegaly drug, Sandostatin LAR. Sandostatin LAR lost its patent in 2010, except in the US where its patent exclusivity ends in 2014. The decline in sales of Sandostatin LAR in the forecast period is expected to be balanced by the launch of acromegaly drug Pasireotide, which is now in Phase III. Eli Lilly constitutes 6% of the global endocrinology market with its drugs Humatrope and Axiron. Humatrope, one of the competitor drugs in the growth hormone deficiency market, witnessed a decline in sales following its patent expiry in 2008. Axiron, underarm testosterone therapy entered in 2010 for the treatment of male hypogonadim. Eli Lilly’s market share in the endocrinology market is expected to rise if Axiron well in the market.

Advanced Formulations of Biological Products are Set to Dominate the Endocrinology Market

The endocrinology market is expected to witness the introduction of innovative and improved formulations and drugs utilizing novel drug delivery technology. Unlike the frequent injections involved in hormone replacement therapy, novel formulations will easily penetrate the market due to high patient compliance. Therefore major pharmaceutical companies are concentrating on developing new formulations and drug delivery routes to establish their presence in the endocrinology market.

Pipeline molecules suggest that R&D is also concentrated more on the development of new formulations of hormones for quick and easy delivery. The most promising pipeline molecules include the newer and better versions of hormones such as LB03002 (sustained release recombinant human growth hormone), C2L (improved formulation version of Sandostatin LAR) and Bio-T-Gel (testosterone gel).

Analysis of major strategic consolidations in the endocrinology market suggests that the licensing of drugs with improved formulation are going to dominate the market. Majority of licensing agreements are signed for novel formulations such as Octreotide SDI, (a needle-free novel drug delivery system for octreotide), C2L, Somatuline Autogel (depot formulation of lanreotide), Straint SR (sustained release formulation of testosterone), Tirosint (levothyroxine liquid in soft gelatin capsule) and Axiron (underarm testosterone lotion). The number of licensing deals for improved formulations is expected to grow in the future as these advanced products will create a highly competitive market.

Pharmacy / Drugs   Market study
Year:   2012
Publisher:   GBI Research
Price:   3,500.00€
More about GBI Research
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE